• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Wellbutrin (bupropion HCl) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010


Summary View



Drug Interactions
  • Addition of pharmacokinetic information from a series of studies concerning drug interactions between bupropion and ritonavir and lopinavir/ritonavir.
  • Addition of ticlopidine and clopidogrel as examples of drugs that are substrates of or inhibitors/inducers of CYP2B6 and thus may interact with bupropion. Addition of statement that bupropion increases the Cmax and AUC of citalopram by 30% and 40%, respectively.


(Wellbutrin XL and SR only)

  • An update to the statement “Do not chew, divide, or crush tablets” to add “as this may lead to an increased risk of adverse effects, including seizures”.